Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × pegfilgrastim × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 6 Breast Neoplasms 6 Lymphoma, Large B-Cell, Diffuse 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma 4 Rhabdomyosarcoma 3 Lymphoma, Non-Hodgkin 3 Leukemia 3 Burkitt Lymphoma 3 Triple Negative Breast Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Neuroblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Urinary Bladder Neoplasms 1 Teratoma 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Sarcoma 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Pain 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Multiple Myeloma 1 Medulloblastoma 1

Interventions

Trastuzumab 13 pertuzumab 8 Docetaxel 6 tucatinib 5 pyrotinib 4 Capecitabine 4 Paclitaxel 3 Carboplatin 2 Ado-Trastuzumab Emtansine 2 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 exemestane 1 dalpiciclib 1 Leuprolide 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03571633 2025-11-26

BREASTIMMU02

Centre Leon Berard

Phase 2 Active not recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡